NCT04727996View on ClinicalTrials.gov

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

December 31, 2024

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

Sitravatinib

120 mg will be administered orally once daily

DRUG

Tislelizumab

200 mg will be administered intravenously (IV) once every 3 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT04727996 - Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter